Keywords
chemotherapy
oral cavity
cheilitis
mucositis
salivary gland dysfunction
therapeutic and preventive measures
How to Cite
Abstract
This study is devoted to one of the most severe complications of the breast cancer patients treatment - oral mucositis, which leads to the interruption of the treatment, makes a bad influence on the disease prognosis, decrease of the treatment efficacy and quality of life of cancer patients.
Heilitis is the most frequent side-effect, which has a highest manifestation rate during the III cycle of chemotherapy - 69.2 ± 9.2% with a subsequent gradual decrease up to 34.6 ± 9.5% at the VI cycle. The appearence of hyposalivation is observed with the maximal rate at II cycle of chemotherapy - 61,5 ± 9,7%, with a subsequent decrease of its manifestations up to 26,9 ± 8,9% at cycle VI. The mucositis-rate increases by the III cycle of chemotherapy up to 73.1 ± 8.9%, with the subsequent decrease of it up to 34.6 ± 9.5% at the VI cycle of chemotherapy. The paraodontal tissues disease was observed more often during the II-IV cycle of chemotherapy - 26,9 ± 8,9%, with a subsequent decrease up to 7,7 ± 5,3% at the VI cycle of chemotherapy.
The authors have developed a complex of the preventive and therapeutic care for these patients, which application contributed to the possible decrease of the side-effects in the oral cavity in comparison to the other group in 1.5 times during the I cycle of chemotherapy (56.9 ± 5.9%) and in 4,5 times at the 6th cycle of chemotherapy (18,1 ± 4,6%). The heilitis-rate was decreased in 5,2 times and paraodontal tissues disease-rate in 13,4 times at I cycle of chemotherapy versus the comparison group, in which there were almost no side-effects at the VI cycle of chemotherapy (1, 4 and 0%, respectively); mucositis-rate was in 2.4 times lower at the I cycle of chemotherapy, up to 8.2 times at the VI cycle of chemotherapy; the hyposalivation was probably in 1,7 times lower, than at the I cycle of chemotherapy, and up to 2,5 times at the V cycle of chemotherapy versus the comparison group.
The authors constitute, the preventive and therapeutic oral care should be prescribed for each cancer patient during the chemotherapy.
Keywords: breast cancer, chemotherapy, oral cavity, cheilitis, mucositis, salivary gland dysfunction, therapeutic and preventive measures.
References
Моник А. Поддерживающая стоматологическая помощь для пациентов с онкологическими заболеваниями / А. Моник, К.Л. Стокман, Ф. Спийкервет // Популярная медицина. – 2002. – Т. 1, № 2. – С. 41–43.
Попруженко Т.В. Химиотерапевтический оральный мукозит: патобиология, лечение, профилактика // Т.В. Попруженко, Т.Д. Углова, С.П. Борис // Теория – практике. Стоматолог Инфо. – Харьков, 2013. – № 3. – С. 14–20.
Рак в Україні, 2015–2016. Захворюваність, смертність, показники діяльності онкологічної служби // Бюлетень Національного канцер-реєстру України № 18. – К., 2017. – 123 с.
Руководство по химиотерапии опухолевых заболеваний / [под ред. Н.И. Переводчиковой]. – 2-е изд., доп. – М.: Практическая медицина, 2013. – С. 432–433.
Сухина И.С. Особенности состояния слизистой оболочки ротовой полости и губ у пациенток с раком молочной железы на этапах адъювантной полихимиотерапии. / И.С. Сухина, И.И. Соколова // Вісник проблем біології та медицини. – 2012 – Вип. 2, том 2 (93). – С. 251–255.
Adverse event management of oral mucositis in patients with breast cancer / S. Seiler, J. Kosse, S. Loibl, C. Jackisch // Breast Care (Basel). – 2014. – 9 (4). – P. 232–237.
Clinical practice guidelines for the prevention and treatment of cancer therapy–induced oral and gastrointestinal mucositis / E.B. Rubenstein, D.E. Peterson, M. Schubert [et al.] // Cancer. – 2004. – Vol. 100, Suppl. 9. – P. 2026–2046.
Efficacy and toxicity profile of pegylated liposomal doxorubicin (Caelyx) in patients with advanced breast cancer / J. Rom, S. Bechstein, C. Domschke [et al.] // Anticancer Drugs. – 2014. – 25 (2). – P. 219–224.
Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial / F. Andr , R. O'Regan, M. Ozguroglu [et al.] // Lancet Oncol. – 2014. – 15 (6). – P. 580–591.
Lalla R.V. Management of oral mucositis in patients who have cancer / R.V. Lalla, S.T. Sonis, D.E. Peterson // Dent. clin. north am. – 2008. – 52(1). – P. 61–77.